No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
AXNX Axonics
- 67.200
- -0.140-0.21%
Close Apr 17 16:00 ET
- 67.200
- 0.0000.00%
Post 17:33 ET
3.43BMarket Cap-560000P/E (TTM)
67.490High67.150Low608.29KVolume67.330Open67.340Pre Close40.93MTurnover1.21%Turnover RatioLossP/E (Static)51.00MShares69.68052wk High5.38P/B3.39BFloat Cap47.59052wk Low--Dividend TTM50.43MShs Float79.915Historical High--Div YieldTTM0.51%Amplitude11.950Historical Low67.281Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
RBC Capital Remains a Hold on Axonics Modulation Technologies (AXNX)
Express News | Axonics Shares Are Trading Lower After the Company and Boston Scientific Receive a Request for Additional Information From the FTC in Connection With the FTC's Review of the Merger Agreement. The Merger Is Now Expected to Be Completed in the Second Half o
Express News | Boston Scientific Earlier Disclosed That On Apr. 3, Co. And Axonics Received Request For Additional Information From FTC In Connection With FTC's Merger Review; Says The Merger Is Now Expected To Be Completed In The Second Half Of 2024
UPDATE 1-FTC Seeks More Information on Boston Scientific's $3.7 Bln Axonics Deal
Boston Scientific, Axonics Merger Prompts FTC to Request Additional Information
By Denny Jacob Boston Scientific and Axonics each received a request for additional information from the Federal Trade Commission regarding a previously agreed upon merger. The medical device manufa
All You Need to Know About Axonics (AXNX) Rating Upgrade to Buy
Comments
Analysts' consensus shows Axonics performing as expected, with no major estimate changes post recent results. Despite a predicted slowdown in revenue growth, Axonics is still expected to outpace the wider industry.
Analysts Have Made A Financial Statement On Axonics, Inc.'s (NASDAQ:AXNX) Full-Year Report 1
Axonics' consistent revenue growth, despite last year's lack of profit, has led to a 33% annual increase in share price over the past five years, making it a potential investment opportunity.
Meghan Scanlon from Boston Scientific forecasts merger to enhance support for urologists handling chronic conditions. Acquisition may improve earnings per share over time, though GAAP earnings may see lesser increase due to related expenses.
Investors believe in Axonics' potential for future revenue growth, supporting higher stock prices despite a high P/S ratio. They discount the chance of a revenue decrease, but risks and other factors must also be considered.
Axonics' strong revenue growth may be driving its stock performance and could be attractive for growth investors. The recent sell-off may open up investment opportunities if long-term growth signs are positive.
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg